Optimal follow-up period after switching to another inhaled corticosteroid/long-acting β2 agonist in patients with asthma: A retrospective study using Japanese administrative claims data
Authors:
Open Access
- 13 October 2022
- journal article
- research article
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 17 (10) , e0276001
Abstract
Switching inhalation devices is a reasonable option if problems with control, adherence, or inhalation technique occur in patients with asthma treated with inhaled corticosteroid (ICS)/long-acting β2 agonist (LABA). However, evidence to determine the extent to which the carefully monitored period persists after switching is insufficient. In this study, we aimed to investigate the duration of the carefully monitored period after switching to another ICS/LABA. This retrospective study used claims data from Japanese health insurance associations from May 2014 to April 2019. A total of 1,951 patients who switched to another ICS/LABA during the study period were selected for analysis. The relative risk of the first exacerbation after switching was calculated for each four-week interval after the switch compared with that before the switch in a self-controlled case series design. We further assessed patient background associated with exacerbations during the follow-up period. In the primary analysis, the risk of asthma exacerbation compared to the control period was derived from a conditional logistic regression model, which showed a significant decrease immediately after the switch (1 to 4 weeks, Odds ratio [OR] 0.37, 95% confidence interval [CI] 0.26–0.54). Subsequently, the risk increased again and was not significantly different from the control period until week 32 (OR 0.55, 95% CI 0.29–1.04). In a sensitivity analysis among patients with a history of exacerbations, up to week 20 was the period of no continuous risk reduction (OR 0.84, 95% CI 0.41–1.70). In the secondary analysis, chronic rhinosinusitis, sleep disorders, and a history of asthma exacerbation were significantly associated with asthma exacerbation. The incidence of exacerbation remained high for approximately 4 to 7 months after patients with asthma switched to another ICS/LABA. Therefore, these patients should be carefully monitored for at least 4 to 7 months and should be re-assessed at an earlier point in time, if necessary.Keywords
Funding Information
- KYORIN Pharmaceutical Co., Ltd.
This publication has 37 references indexed in Scilit:
- A polymorphism in HLA-G modifies statin benefit in asthmaThe Pharmacogenomics Journal, 2014
- Asthma control in patients receiving inhaled corticosteroid and long-acting beta2-agonist fixed combinations. A real-life study comparing dry powder inhalers and a pressurized metered dose inhaler extrafine formulationBMC Pulmonary Medicine, 2011
- Effect of Esomeprazole 40 mg Once or Twice Daily on Asthma: A Randomized, Placebo-controlled StudyAmerican Journal of Respiratory and Critical Care Medicine, 2010
- The Prevalence of Nonadherence in Difficult AsthmaAmerican Journal of Respiratory and Critical Care Medicine, 2009
- Inhaled corticosteroids for asthma: impact of practice level device switching on asthma controlBMC Pulmonary Medicine, 2009
- The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studiesJournal of Clinical Epidemiology, 2008
- Glucocorticoid Receptor Nuclear Translocation in Airway Cells after Inhaled Combination TherapyAmerican Journal of Respiratory and Critical Care Medicine, 2005
- Methods of delivering drugsBMJ, 2005
- Gastroesophageal reflux: a potential asthma triggerImmunology and Allergy Clinics of North America, 2005
- Scientific rationale for inhaled combination therapy with long-acting β2-agonists and corticosteroidsEuropean Respiratory Journal, 2002